基本信息
浏览量:147
职业迁徙
个人简介
About Dr. Wang
I am a Professor in the department of Lymphoma & Myeloma at MD Anderson. I obtained my M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. I completed my clinical training as a resident at Norwalk Hospital, Norwalk, Conn., and as a Fellow in Oncology and in Hematology at MD Anderson.
I have published more than 150 peer-reviewed papers and have presented my work at meetings nationally and internationally. I am the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials at MD Anderson.
During the past 15 years, I have focused on preclinical and clinical research and established a MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. My clinical research of the Bruton’s tyrosine kinase inhibitor ibrutinib was published in the New Eng. J. Med. in 2013. I am currently acting as National PI of the multisite international phase 5 registration trial for ibrutinib in MCL. I am also the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.
I am a Professor in the department of Lymphoma & Myeloma at MD Anderson. I obtained my M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. I completed my clinical training as a resident at Norwalk Hospital, Norwalk, Conn., and as a Fellow in Oncology and in Hematology at MD Anderson.
I have published more than 150 peer-reviewed papers and have presented my work at meetings nationally and internationally. I am the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials at MD Anderson.
During the past 15 years, I have focused on preclinical and clinical research and established a MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. My clinical research of the Bruton’s tyrosine kinase inhibitor ibrutinib was published in the New Eng. J. Med. in 2013. I am currently acting as National PI of the multisite international phase 5 registration trial for ibrutinib in MCL. I am also the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.
研究兴趣
论文共 746 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer Researchno. 6_Supplement (2024): 676-676
Geoffrey Chong,Franck Morschhauser,Alex Herrera, Ki-Seong Eom,Tae Min Kim,Michael Wang, Connor Hall,Fathima Zumla Cader, Kaitlyn Beyfuss, Patricia Cheung, Wei Quan,Shringi Sharma,
Cancer Researchno. 7_Supplement (2024)
BLOODno. 5 (2024): 404-416
Human Pathology (2024): 1-7
Rudra Prasad Dutta,Heng-Huan Lee,Violetta V Leshchenko, Ravi Prakash Shukla,Yang Liu,Jian Jin,Michael Wang, Samir Parekh
Cancer Researchno. 6_Supplement (2024): 649-649
Bloodno. 2 (2024): S14
Modern Pathologyno. 2 (2024): 100405-100405
Steven Le Gouill, Monika ugosz-Danecka,Simon Rule,Pier Luigi Zinzani,Andre Goy, Stephen D. Smith,Jeanette K. Doorduijn,Carlos Panizo,Bijal D. Shah,Andrew J. Davies,Richard Eek,Eric Jacobsen,
Haematologicano. 1 (2024): 343-350
Fangfang Yan,Vivian Jiang,Alexa Jordan,Yuxuan Che,Yang Liu,Qingsong Cai,Yu Xue,Yijing Li, Joseph McIntosh, Zhihong Chen,Jovanny Vargas,Lei Nie,
Experimental Hematology & Oncologyno. 1 (2024): 14-14
Anath C. Lionel, Ashwath Gurumurthi, Ahmed Fetooh,Rami Eldaya,Sairah Ahmed,Swaminathan P. Iyer,Loretta J. Nastoupil,Jason Westin,Ranjit Nair,Luis Fayad,Luis Malpica,Sudhakar Tummala,
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn